Date-time group

Bryn Pharma to Present Positive Clinical Data Supporting Use of Its Epinephrine Nasal Spray in Adults with or without Congestion at 2023 ACAAI Annual Meeting

Retrieved on:

Thursday, November 9, 2023

LEBANON, N.J., Nov. 9, 2023 /PRNewswire/ -- Bryn Pharma, LLC, a privately held pharmaceutical company dedicated to finding a novel and convenient way for patients and caregivers to treat anaphylaxis, announced today that positive clinical data supporting use of its epinephrine nasal spray (ENS) – known as NDS1C – in adults with or without congestion, will be presented during the 2023 American College of Allergy Asthma and Immunology Annual Scientific Meeting (ACAAI). The meeting is being held November 9-13, 2023, in Anaheim, California.

Key Points:

The results showed that NDS1C, in fact, provides enhanced absorption in adults with or without congestion compared to intramuscular (IM) epinephrine and the epinephrine autoinjector (EAI).
"Unlike other epinephrine nasal spray candidates in development, NDS1C is the only intranasal epinephrine product with publicly available data demonstrating enhanced absorption in the presence of congestion.
In the first period, both cohorts received 13.2 mg of NDS1C administered by two consecutive sprays, with congestion induced by NAC.
The poster can be accessed here and presentations details are as follows:
Date & Time: Friday, November 10 at 3:15 p.m. PT

Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Retrieved on:

Monday, November 6, 2023

SEATTLE, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the presentation of new positive data from its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, the company’s VISTA blocking immunotherapy, in patients with advanced solid tumors at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, presented the company’s poster unveiling the new clinical data.

Key Points:

Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, presented the company’s poster unveiling the new clinical data.
VISTA blocking immunotherapy KVA12123 has performed remarkably well in demonstrating excellent safety and tolerability in the clinic.
KVA12123 achieved a greater than 90% VISTA RO at the 30 mg dose indicating that KVA12123 may be approaching an optimal clinical dose.
Additional monotherapy safety and efficacy data and combination therapy clinical data are anticipated in the second quarter of 2024.

Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting

Retrieved on:

Friday, November 3, 2023

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company presented new preclinical data on povetacicept in myasthenia gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting (AANEM), November 1-3, 2023 in Phoenix, Arizona.

Key Points:

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company presented new preclinical data on povetacicept in myasthenia gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting (AANEM), November 1-3, 2023 in Phoenix, Arizona.
In addition, the Company presented safety, tolerability, pharmacokinetic, and pharmacodynamic data from RUBY-1, a phase 1 study of povetacicept in healthy adult volunteers.
In a model of murine experimental autoimmune myasthenia gravis (EAMG), povetacicept improved disease activity, with clinical scores superior to treatment with either the FcRn inhibitor efgartigimod or an anti-CD20 depleting antibody.
“These data indicate that povetacicept might deliver efficacy superior to some therapeutics currently in clinical use for myasthenia gravis and other autoantibody-related neurological diseases.

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress

Retrieved on:

Wednesday, November 1, 2023

These new findings bolster KarXT’s earlier data, demonstrating clinically meaningful symptom reduction along with strong tolerability,” said Stephen Brannan, M.D., chief medical officer of Karuna Therapeutics.

Key Points:

These new findings bolster KarXT’s earlier data, demonstrating clinically meaningful symptom reduction along with strong tolerability,” said Stephen Brannan, M.D., chief medical officer of Karuna Therapeutics.
In September 2023, the company filed an NDA for KarXT for the treatment of schizophrenia in adults to the U.S. FDA.
The NDA submission is supported by efficacy and long-term safety data from the EMERGENT program, the clinical program evaluating KarXT as a treatment for schizophrenia.
The EMERGENT program includes the three completed positive EMERGENT-1, EMERGENT-2, and EMERGENT-3 trials evaluating the efficacy and safety of KarXT compared to placebo, and the EMERGENT-4 and EMERGENT-5 trials evaluating the long-term safety of KarXT.

Charlie Puth Official Fan Club App “humy” Available in Korea

Retrieved on:

Friday, October 20, 2023

MIXI Inc. (Shibuya-ku, Tokyo, President and CEO: Koki Kimura) announced that Charlie Puth official fan club App “humy” is now available in Korea from October 17, 2023.

Key Points:

MIXI Inc. (Shibuya-ku, Tokyo, President and CEO: Koki Kimura) announced that Charlie Puth official fan club App “humy” is now available in Korea from October 17, 2023.
View the full release here: https://www.businesswire.com/news/home/20231019795486/en/
humy with Charlie Puth (Photo: Business Wire)
Charlie, who became a hot topic last year with his collaboration with Jong-Guk (BTS), will conduct live performances in Korea from October 20 to 22.
Charlie Puth himself will post photos and videos of his daily life on the social media for fans only.
His visit to Korea will be from October 20-22, with three performances at the KSPO DOME in Seoul Olympic Park.

Kineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted for Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023

Retrieved on:

Thursday, October 12, 2023

Annual general meeting, Immunoglobulin G, Date, Abstract, Pembrolizumab, VISTA, SITC, Cancer, Society, Society for Immunotherapy of Cancer, Clinical trial, Date-time group, Immunotherapy, Patient, Pharmaceutical industry, Communications satellite, Kineta

SEATTLE, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that two abstracts have been accepted for poster presentation on Kineta’s immuno-oncology therapies at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held November 1-5, 2023, in San Diego, California and virtually.

Key Points:

SEATTLE, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that two abstracts have been accepted for poster presentation on Kineta’s immuno-oncology therapies at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held November 1-5, 2023, in San Diego, California and virtually.
Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will be presenting posters with new clinical data on KVA12123, the company’s VISTA blocking immunotherapy currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors, as well as new preclinical data on Kineta’s anti-CD27 agonist antibody program.
Title: VISTA-101 – A phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, alone and in combination with pembrolizumab in advanced solid tumors
Date / Time: Saturday, November 4 at 9:00 A.M. – 7:00 P.M. Pacific Time
Date / Time: Friday, November 3 at 9:00 A.M. – 7:00 P.M. Pacific Time
Abstract titles are now available on the SITC website.
Posters will be made available on the Kineta website following presentations at the conference.

Vergent Bioscience to Present Phase 2 Clinical Data for VGT-309 at IASLC 2023 World Conference on Lung Cancer

Retrieved on:

Wednesday, August 16, 2023

Oncology, Robotics, Health, Technology, Surgery, Clinical Trials, Biotechnology, Suntec Singapore Convention and Exhibition Centre, Surgeon, Convention center, Neoplasm, International Association, Lung cancer, Date-time group, MIS, Conference, Safety, Pharmaceutical industry, Medical imaging

Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, and its wholly owned subsidiary Vergent Bioscience Australia Pty Ltd, announced that new clinical data from a Phase 2 study of the company’s investigational agent VGT-309 will be presented at the 2023 World Conference on Lung Cancer (#WCLC23) hosted by the International Association for the Study of Lung Cancer (IASLC), taking place September 9-12, 2023, in Singapore.

Key Points:

Vergent Bioscience , a clinical-stage biotechnology company developing tumor-targeted imaging agents, and its wholly owned subsidiary Vergent Bioscience Australia Pty Ltd, announced that new clinical data from a Phase 2 study of the company’s investigational agent VGT-309 will be presented at the 2023 World Conference on Lung Cancer (#WCLC23) hosted by the International Association for the Study of Lung Cancer (IASLC), taking place September 9-12, 2023, in Singapore.
“We’ve steadily advanced the VGT-309 clinical program and look forward to sharing the latest results from our Phase 2 study evaluating the safety, efficacy, and dosing of this novel compound,” said John Santini, Ph.D., president and chief executive officer at Vergent Bioscience.
“VGT-309 has the potential to fill deficits in tumor visualization during surgery to optimize outcomes for patients.”
Early Phase 1 and 2 clinical trials evaluating VGT-309 in lung cancer yielded compelling safety and efficacy data that support the agent’s ability to help surgeons see difficult-to-find or previously undetected tumors in real-time, ensuring all tumor tissue is removed during minimally invasive (MIS) and robotic-assisted surgical procedures.
Following are details about the VGT-309 presentation at the 2023 WCLC:
Date/Time: 2:30 - 3:30 PM Singapore/2:30 – 3:30 AM ET, September 11, 2023
Location: Suntec Singapore Convention & Exhibition Centre, Room 405C

Identity and Access Management, Cybersecurity Solutions Provider BIO-key International Hosts Q2 Conference Call Tue. Aug. 15 at 10am ET

Retrieved on:

Monday, August 7, 2023

International, Q&A, Identity, Access management, IBB, Date-time group, CFO, IAM, Identity management, Cryptocurrency, WALL

WALL, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of Identity and Access Management (IAM) and Identity-Bound Biometric (IBB) solutions, will host its second quarter investor conference call, Tuesday, August 15th at 10 a.m.

Key Points:

WALL, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of Identity and Access Management (IAM) and Identity-Bound Biometric (IBB) solutions, will host its second quarter investor conference call, Tuesday, August 15th at 10 a.m.
ET.
Mike DePasquale, Chairman & CEO and Cecilia Welch, CFO will lead the call and Q&A session.
ET
Call Dial In #: 1-877-418-5460 U.S. or 1-412-717-9594 International
Live Webcast / Replay: Webcast & Replay Link – Available for 3 months.

Applied DNA to Report Second Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, May 11, 2023

Retrieved on:

Wednesday, May 3, 2023

Health, Biotechnology, Webcast, Applied Biosystems, Date-time group, Polymerase chain reaction, PCR, Phonograph record

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release financial results for the three months ended March 31, 2023 after the market close on Thursday, May 11, 2023.

Key Points:

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release financial results for the three months ended March 31, 2023 after the market close on Thursday, May 11, 2023.
The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m.
Date & Time: Thursday, May 11 @ 4:30 p.m.
The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

Orchard Therapeutics Announces New Clinical and Pre-clinical Data at ASGCT 2023

Retrieved on:

Wednesday, May 3, 2023

Abstract, POC, Gene, MPS, Stem cell, Sanfilippo, Frontotemporal dementia, Cell, HSC, Therapy, Date-time group, FTD, Society, Hurler, Pharmaceutical industry, Communications satellite

BOSTON and LONDON, May 03, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced six presentations from across its hematopoietic stem cell (HSC) gene therapy platform will be featured at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place May 16-20, 2023, in Los Angeles.

Key Points:

BOSTON and LONDON, May 03, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced six presentations from across its hematopoietic stem cell (HSC) gene therapy platform will be featured at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place May 16-20, 2023, in Los Angeles.
In addition, several abstracts from the company’s pre-clinical research programs demonstrate the therapeutic potential of HSC gene therapy to address genetic sub-types of frontotemporal dementia (FTD) and Crohn’s disease, as well as chronic autoimmune disorders.
“Our presence at ASGCT highlights the transformative impact and broad applicability of our platform,” said Leslie Meltzer, Ph.D., chief medical officer of Orchard Therapeutics.
“Taken together, the data from our MPS programs continues to show the potential of a one-time HSC gene therapy to address some of the most severe manifestations of this complex group of multi-system diseases.